Targeted therapy in the treatment of uterine serous carcinoma

Pharmacogenomics. 2015 Jan;16(2):97-9. doi: 10.2217/pgs.14.176.
No abstract available

Keywords: HER2; PIK3CA; mTOR; targeted therapy; uterine serous carcinoma.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Cystadenocarcinoma, Serous / drug therapy*
  • Cystadenocarcinoma, Serous / genetics
  • Female
  • Gene Amplification / genetics
  • Humans
  • Molecular Targeted Therapy* / methods
  • Receptor, ErbB-2 / drug effects
  • Receptor, ErbB-2 / genetics
  • Uterine Neoplasms / drug therapy*
  • Uterine Neoplasms / genetics

Substances

  • Antineoplastic Agents
  • ERBB2 protein, human
  • Receptor, ErbB-2